Drug Database · Clinicians

Bleomycin

Brands (9) Bleoace, Bleocel, Bleomaxcin…Show all

Antineoplastic agent (cytotoxic antibiotic); Antineoplastic (cell cycle-specific agent); and others PH FDA category

Rx · Prescription drug9 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 640602f9-a7df-46f0-a9b1-19c471008bee, version date April 17, 2026 (Bleomycin · Meitheal Pharmaceuticals Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Bleomycin for Injection, USP should be considered a palliative treatment.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva.

The response to Bleomycin for Injection, USP is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection, USP is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Contraindications

CONTRAINDICATIONS Bleomycin for injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Because of the possibility of an anaphylactoid reaction, lymphoma patients should be treated with 2 units or less for the first 2 doses. If no acute reaction occurs, then the regular dosage schedule may be followed. The following dose schedule is recommended: Squamous cell carcinoma, non-Hodgkin's lymphoma, testicular carcinoma – 0.25 to 0.50 units/kg (10 to 20 units/m 2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.

Hodgkin's Disease – 0.25 to 0.50 units/kg (10 to 20 units/m 2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly. After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given. Pulmonary toxicity of bleomycin for injection appears to be dose-related with a striking increase when the total dose is over 400 units.

Total doses over 400 units should be given with great caution. Note: When bleomycin for injection is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses. Improvement of Hodgkin's disease and testicular tumors is prompt and noted within 2 weeks. If no improvement is seen by this time, improvement is unlikely.

Squamous cell cancers respond more slowly, sometimes requiring as long as 3 weeks before any improvement is noted. Malignant Pleural Effusion – 60 units administered as a single dose bolus intrapleural injection (see ADMINISTRATION: Intrapleural). Use in Patients with Renal Insufficiency The following dosing reductions are proposed for patients with creatinine clearance (CrCL) values of less than 50 mL/min: CrCL can be estimated from the individual patient's measured serum creatinine (Scr) values using the Cockcroft and Gault formula: Males CrCL = [weight × (140 – Age)]/(72 × Scr) Females CrCL = 0.85 × [weight × (140 – Age)]/(72 × Scr) Where CrCL in mL/min/1.73 m², weight in kg, age in years, and Scr in mg/dL.

Patient CrCL (mL/min) Bleomycin for Injection Dose (%) 50 and above 100 40 to 50 70 30 to 40 60 20 to 30 55 10 to 20 45 5 to 10 40

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, clinical pharmacology)

Patients with Renal Insufficiency The following dosing reductions are proposed for patients with creatinine clearance (CrCL) values of less than 50 mL/min: CrCL can be estimated from the individual patient's measured serum creatinine (Scr) values using the Cockcroft and Gault formula: Males CrCL = [weight × (140 – Age)]/(72 × Scr) Females CrCL = 0.85 × [weight × (140 – Age)]/(72 × Scr) Where CrCL in mL/min/1.73 m², weight in kg, age in years, and Scr in mg/dL. Patient CrCL (mL/min) Bleomycin for Injection Dose (%) 50 and above 100 40 to 50 70 30 to 40 60 20 to 30 55 10 to 20 45 5 to 10 40

Renal Insufficiency Renal insufficiency markedly alters bleomycin elimination. The terminal elimination half-life increases exponentially as the creatinine clearance decreases. Dosing reductions were proposed for patients with creatinine clearance values of <50 mL/min (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness of bleomycin in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use In clinical trials, pulmonary toxicity was more common in patients older than 70 years than in younger patients (see BOXED WARNING, WARNINGS, and ADVERSE REACTIONS: Pulmonary). Other reported clinical experience has not identified other differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Bleomycin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Dosage forms

Philippines

  • Powder for solution for injection: 15 Units
  • Lyophilized powder for injection: 15 units
  • Lyophilized power for injection: 15 Units
  • Powder for injection: 15 Units
  • Powder for solutin for injection: 15 Units

Registered products in the Philippines

9 products registered with the Food and Drug Administration (FDA) Philippines list Bleomycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products9
Philippine FDA-registered products for Bleomycin
Package insert
BleoaceBleomycin (as Sulfate)
15 Units Powder for Solution for Injection (IM/IV/SC)5 mL-capacity Type I Tubular Clear Glass Vial with Grey Butyl Rubber Stopper and White Aluminum Seal [Box of 1’s]
RxVAT-exempt
Venus Remedies LimitedIndia
Genace Pharma DistributorImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Private Limited
DRP-13391-02
Feb 16, 2028
BleocelBleomycin (as sulfate)
15 Units Lyophilized Power for Injection (IM/IV/SC)5 mL USP Type I Clear and Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica Inc.
DRP-6156
Jun 2, 2031
BleomaxcinBleomycin (as Sulfate)
15 units Lyophilized Powder for Injection (IM/IV/SC)Clear molded Gray USP Type-I Glass Vial with slotted butyl rubber stopper, Aluminum seal, and Scarlet red color flip off seal (Box of 1's in a Box of 10's)
RxVAT-exempt
United Biotech Pvt. Ltd.India
Dreamax Incorporated
DRP-17183
Oct 17, 2030
BleomedBleomycin (as Sulfate)
15 Units Powder For Solutin For Injection (IM/IV/SC)5 mL-capacity Type I Tubular Clear Glass Vial with Grey Butyl Rubber Stopper and White Aluminum Seal [Box of 1's]
RxVAT-exempt
Venus Remedies LimitedIndia
Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Private Limited
DRP-13391
Feb 16, 2028
BleonovBleomycin (as sulfate)
15 Units Powder for Solution for Injection (IM/IV/SC)5 mL- capacity Type I Tubular Clear Glass Vial with Grey Butyl Rubber Stopper and White Aluminum Seal [Box of 1's]
RxVAT-exempt
Venus Remedies LimitedIndia
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Private Limited
DRP-13391-01
Feb 16, 2028
BleophilBleomycin (as Sulfate)
15 Units Powder for Solution for Injection (IM/IV/SC)5 mL-capacity Type I Tubular Clear Glass Vial with Grey Butyl Rubber Stopper and White Aluminum Seal (Box of 1’s)
RxVAT-exempt
Venus Remedies LimitedIndia
Oncophil Pharma And Medical Supplies DistributionImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Private Limited
DRP-13391-04
Feb 16, 2028
Bloicin-SBleomycin (as sulfate)
15 Units Powder for Injection (IV/IM/SC/IP)USP Type I Colorless Glass Vial with Rubber Stopper and Red Flip-off Seal x 1.5 mL (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY28639
May 14, 2028
MedimycinBleomycin (as sulfate)
15 units Powder for Solution for Injection (IM/IV/SC)5 mL-capacity Type I Tubular Clear Glass Vial with Grey Butyl Rubber Stopper and White Aluminum Seal (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.Trader: Prime Pharmaceuticals Private Limited
DRP-13391-03
Feb 16, 2028
Tumocin-15Bleomycin (as Sulfate)
15 Units Lyophilized Powder for Injection (IV/IM/SC)USP Type I Flint Glass Vial x 5 mL (Box of 1's)
RxVAT-exempt
Neon Laboratories Ltd.India
Ambica International Corporation
DRP-5509
Sep 12, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Patients receiving bleomycin must be observed carefully and frequently during and after therapy. It should be used with extreme caution in patients with significant impairment of renal function or compromised pulmonary function. Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis and death.

Although this is age and dose related, the toxicity is unpredictable. Frequent roentgenograms are recommended (see ADVERSE REACTIONS: Pulmonary). A severe idiosyncratic reaction (similar to anaphylaxis) consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.

Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses (see ADVERSE REACTIONS: Idiosyncratic Reactions). Renal or hepatic toxicity, beginning as a deterioration in renal or liver function tests, have been reported. These toxicities may occur at any time after initiation of therapy.

Usage in Pregnancy Pregnancy “Category D” Bleomycin can cause fetal harm when administered to a pregnant woman. It has been shown to be teratogenic in rats. Administration of intraperitoneal doses of 1.5 mg/kg/day to rats (about 1.6 times the recommended human dose on a unit/m 2 basis) on days 6 to 15 of gestation caused skeletal malformations, shortened innominate artery and hydroureter.

Bleomycin is abortifacient but not teratogenic in rabbits at intravenous doses of 1.2 mg/kg/day (about 2.4 times the recommended human dose on a unit/m 2 basis) given on gestation days 6 to 18. There have been no studies in pregnant women. If bleomycin is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.

Women of childbearing potential should be advised to avoid becoming pregnant during therapy with bleomycin.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Drugs that Can Affect Renal Clearance Because bleomycin is eliminated predominantly through renal excretion, the administration of nephrotoxic drugs with bleomycin may affect its renal clearance. Specifically, in one report of 2 children receiving concomitant cisplatin with bleomycin, total body clearance of bleomycin decreased from 39 to 18 mL/min/m 2 as the cumulative dose of cisplatin exceeded 300 mg/m 2.

Terminal half-life of bleomycin also increased from 4.4 to 6 hours. Fatal bleomycin pulmonary toxicity has been reported in a patient with unrecognized cisplatin-induced oliguric renal failure.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Pulmonary The most serious side effects are pulmonary adverse reactions, occurring in approximately 10% of treated patients. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Approximately 1% of patients treated have died of pulmonary fibrosis. Pulmonary toxicity is both dose and age related, being more common in patients over 70 years of age and in those receiving over 400 units total dose.

This toxicity, however, is unpredictable and has been seen in young patients receiving low doses. Some published reports have suggested that the risk of pulmonary toxicity may be increased when bleomycin is used in combination with G-CSF (filgrastim) or other cytokines. However, randomized clinical studies completed to date have not demonstrated an increased risk of pulmonary complications in patients treated with bleomycin and G-CSF.

Because of lack of specificity of the clinical syndrome, the identification of patients with pulmonary toxicity due to bleomycin has been extremely difficult. The earliest symptom associated with bleomycin pulmonary toxicity is dyspnea. The earliest sign is fine rales. Radiographically, bleomycin-induced pneumonitis produces nonspecific patchy opacities, usually of the lower lung fields.

The most common changes in pulmonary function tests are a decrease in total lung volume and a decrease in vital capacity. However, these changes are not predictive of the development of pulmonary fibrosis. The microscopic tissue changes due to bleomycin toxicity include bronchiolar squamous metaplasia, reactive macrophages, atypical alveolar epithelial cells, fibrinous edema, and interstitial fibrosis.

The acute stage may involve capillary changes and subsequent fibrinous exudation into alveoli producing a change similar to hyaline membrane formation and progressing to a diffuse interstitial fibrosis resembling the Hamman-Rich syndrome. These microscopic findings are nonspecific; e.g., similar changes are seen in radiation pneumonitis and pneumocystic pneumonitis.

To monitor the onset of pulmonary toxicity, roentgenograms of the chest should be taken every 1 to 2 weeks (see WARNINGS). If pulmonary changes are noted, treatment should be discontinued until it can be determined if they are drug related. Recent studies have suggested that sequential measurement of the pulmonary diffusion capacity for carbon monoxide (DL co) during treatment with bleomycin may be an indicator of subclinical pulmonary toxicity.

It is recommended that the DL co be monitored monthly if it is to be employed to detect pulmonary toxicities, and thus the drug should be discontinued when the DL co falls below 30% to 35% of the pretreatment value. Because of bleomycin's sensitization of lung tissue, patients who have received bleomycin are at greater risk of developing pulmonary toxicity when oxygen is administered in surgery.

While long exposure to very high oxygen concentrations is a known cause of lung damage, after bleomycin administration, lung damage can occur at lower concentrations that are usually considered safe. Suggested preventive measures are: Maintain FIO 2 at concentrations approximating that of room air (25%) during surgery and the postoperative period.

Monitor carefully fluid replacement, focusing more on colloid administration rather than crystalloid. Sudden onset of an acute chest pain syndrome suggestive of pleuropericarditis has been reported during bleomycin infusions. Although each patient must be individually evaluated, further courses of bleomycin do not appear to be contraindicated.

Pulmonary adverse events which may be related to the intrapleural administration of bleomycin have been reported. Idiosyncratic Reactions In approximately 1% of the lymphoma patients treated with bleomycin, an idiosyncratic reaction, similar to anaphylaxis clinically, has been reported. The reaction may be immediate or delayed for several hours, and usually occurs after the first or second dose (see WARNINGS).

It consists of hypotension, mental confusion, fever, chills, and wheezing. Treatment is symptomatic including volume expansion, pressor agents, antihistamines, and corticosteroids. Integument and Mucous Membranes These adverse reactions have been reported in approximately 50% of treated patients. They consist of erythema, rash, striae, vesiculation, hyperpigmentation, and tenderness of the skin.

Hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis have also been reported. It was necessary to discontinue bleomycin therapy in 2% of treated patients because of these toxicities. Scleroderma-like skin changes have been reported. Skin toxicity is a relatively late manifestation usually developing in the second and third week of treatment after 150 to 200 units of bleomycin have been administered and appears to be related to the cumulative dose.

Intrapleural administration of bleomycin has been associated with local pain. Hypotension possibly requiring symptomatic treatment has been reported. Death has been reported in association with bleomycin pleurodesis in seriously ill patients. Other Vascular toxicities coincident with the use of bleomycin in combination with other antineoplastic agents have been reported.

The events are clinically heterogeneous and may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (HUS), or cerebral arteritis. Various mechanisms have been proposed for these vascular complications. There are also reports of Raynaud's phenomenon occurring in patients treated with bleomycin in combination with vinblastine with or without cisplatin or, in a few cases, with bleomycin as a single agent.

It is currently unknown if the cause of Raynaud's phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, hypomagnesemia, or a combination of any of these factors. Fever, chills, and vomiting have been reported. Anorexia and weight loss have been reported and may persist long after termination of this medication.

Pain at tumor site, phlebitis, and other local reactions have been reported. Malaise has been reported. To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Pregnancy “Category D” (See WARNINGS.)

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued by women receiving bleomycin therapy.

Mechanism of action

Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. Bleomycin is known to cause single, and to a lesser extent, double-stranded breaks in DNA. In in vitro and in vivo experiments, bleomycin has been shown to cause cell cycle arrest in G2 and in mitosis. When administered into the pleural cavity in the treatment of malignant pleural effusion, bleomycin acts as a sclerosing agent.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Excretion The primary route of elimination is via the kidneys.

About 65% of the administered intravenous dose is excreted in urine within 24 hours.

In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.

Total body clearance and renal clearance averaged 51 mL/min/m 2 and 23 mL/min/m 2 , respectively.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics Absorption Bleomycin is rapidly absorbed following either intramuscular, subcutaneous, intraperitoneal, or intrapleural administration reaching peak plasma concentrations in 30 to 60 minutes. Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.

Following intramuscular doses of 1 to 10 units/m 2, both peak plasma concentration and AUC increased in proportion with the increase of dose. Following intravenous bolus administration of 30 units of bleomycin to one patient with a primary germ cell tumor of the brain, a peak CSF level was 40% of the simultaneously-obtained plasma level and was attained in 2 hours after drug administration.

The area under the bleomycin CSF concentration x time curve was 25% of the area of the bleomycin plasma concentration x time curve. Distribution Bleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m 2 in patients following a 15 units/m 2 intravenous bolus dose. Protein binding of bleomycin has not been studied.

Metabolism Bleomycin is inactivated by a cytosolic cysteine proteinase enzyme, bleomycin hydrolase. The enzyme is widely distributed in normal tissues with the exception of the skin and lungs, both targets of bleomycin toxicity. Systemic elimination of the drug by enzymatic degradation is probably only important in patients with severely compromised renal function.

Excretion The primary route of elimination is via the kidneys. About 65% of the administered intravenous dose is excreted in urine within 24 hours. In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.

Total body clearance and renal clearance averaged 51 mL/min/m 2 and 23 mL/min/m 2, respectively. Following intrapleural administration to patients with normal renal function, a lower percentage of drug (40%) is recovered in the urine, as compared to that found in the urine after intravenous administration.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Bleomycin (as Sulfate) 15 IU Vial amp/vial₱950.00–₱2,201.00Reference ₱950.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Bleomycin (as sulfate)
PNF listingInj.: powder, 15 IU ampul/vial (IM, IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Bleomycin · Meitheal Pharmaceuticals Inc. [US FDA-approved label, version 3, April 17, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=640602f9-a7df-46f0-a9b1-19c471008bee
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .